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1  | INTRODUC TION
Nephrogenesis in humans is completed by 36 weeks of gesta-
tion and can be interrupted or altered by prematurity, medica-
tion and poor intrauterine growth.1 The total glomerular filtration 
rate is the product of single-nephron filtration multiplied by total 
nephron number. Serum creatinine (SCr) measurements remain 
the most commonly used method of assessing renal function in 
neonates.2 Measurement of serum creatinine is based on a tech-
nique first described by Professor Max Jaffe in 1886.3 In 1926, 
Rehberg proposed that due to its clearance properties, SCr could 
be used to determine glomerular filtration rate (GFR).4 Despite 
subsequent studies showing that SCr has several limitations, SCr 
measurements continue to be used because of cost and conveni-
ence. SCr measured soon after birth reflects maternal creatinine.5 
Furthermore, there is a passive reabsorption of creatinine in the 
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Abstract
Aim: We carried out a longitudinal cohort study to measure serial CysC (Cystatin C) 
in a cohort of neonates born preterm until the age of 2 years. We hypothesised that 
CysC levels are independent of body weight and would not vary with gestational age.
Methods: This prospective cohort study was conducted from August 2014 until 
October 2016, and follow-up was completed in October 2018. Preterm infants at 
less than 28 weeks of gestation (extremely preterm infants) were recruited and fol-
lowed up until the age of 24 months. Blood samples for measurement of CysC were 
collected at regular intervals.
Results: We recruited 58 preterm neonates with mean gestation was 26.2 (1.5) 
weeks, and a mean birth weight was 917 (140) g. One-way analysis of variance 
(ANOVA) did not show any significant difference in CysC levels between 28, 32 and 
37 weeks' gestation (P = .09) despite a significant increase in body weight (P < .001). 
The mean CysC level was higher in the neonatal period and subsequently plateaued 
by 24 months.
Conclusion: Serum CysC level is independent of body weight and not influenced by 
postnatal age nor by gender.
K E Y W O R D S
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renal tubules, rendering GFR estimate inaccurate.6 This is to a cer-
tain extent compensated for by the Jaffe method which is known 
to falsely elevate SCr as a result of non-specific protein and other 
interferences such as Bilirubin, which is physiologically elevated 
during the newborn period.6 Finally, it can be influenced by muscle 
mass and muscle wasting. Also, SCr levels are extremely low in 
young infants (due to low muscle mass); thus, measures of creati-
nine will always lack the analytical sensitivity and are of limited 
value in helping clinicians to determine accurately renal func-
tion, especially in young infants.7 Alternative enzymatic methods 
for determining creatinine have been suggested because they 
are highly sensitive, and background interferences are reduced.8 
However, these are not routinely available.
CysC, a product of cell metabolism, is increasingly being 
recognised as a more reliable biomarker of renal function.6 It is 
a low-molecular-mass (13 kDa) basic protein that belongs to the 
CysC superfamily of reversible inhibitors of cysteine proteases. 
This biomarker is produced at a constant rate by all nucleated 
cells, freely filtered by the glomerulus and not reabsorbed in 
renal tubules, making it an ideal biomarker measure of GFR. CysC 
is also independent of muscle mass, and in the newborn, it does 
not correlate with maternal CysC levels.5 A systematic review by 
Nakhjavan et al9 concluded that CysC can be a suitable alterna-
tive to traditional diagnostic measures and provides an acceptable 
prognostic value for the prediction of AKI in children. However, 
data on CysC measurements in neonates and infants are rather 
limited.7 Therefore, we carried out a longitudinal cohort study to 
measure CysC in a cohort of neonates born preterm and to follow 
them up with serial measurements until the age of 2 years. We 
postulated that CysC would be independent of body weight and 
would not vary with gestational age.
2  | METHODS
This longitudinal cohort study was conducted in the Department 
of Neonatology, Townsville Hospital, Queensland, Australia. The 
recruitment was conducted from August 2014 until October 2016, 
and follow-up was completed in October 2018. The study popula-
tion consists of preterm babies >23 weeks gestation admitted to the 
neonatal unit. Preterm infants at less than 28 weeks of gestation 
(extremely preterm infants), with birth weights between the 10th 
and 90th centile (appropriate for gestational age (AGA)), admitted 
to the neonatal department during the study period were eligible 
to participate in this study. Gestational age as determined by first 
trimester ultrasound scan was used. These infants were then fol-
lowed from term corrected (37 postmenstrual age (PMA)) upon dis-
charge from the neonatal unit at ages of 6, 12 and 24 months. Infants 
with antenatally diagnosed renal abnormalities, growth restriction 
(weight < 10th centile) and no parental consent were excluded from 
this study. Data from a cohort of term infants (gestation > 37 weeks) 
admitted during the same period for minor neonatal conditions such 
as neonatal jaundice, risk of sepsis and poor feeding were recruited 
with parents’ consent as control. The Townsville Health District 
Human Research Ethics Committee approved this study, which 
was conducted following the tenets of the Declaration of Helsinki. 
Written consent was obtained from parents of all infants who partic-
ipated in this study. STrengthening the Reporting of OBservational 
studies in Epidemiology (STROBE) check list was utilised in reporting 
this study.10
CysC concentrations were measured in serum samples using an 
immunoturbidimetric assay designed for use on the Beckman AU480 
automated analyser platform (Gentian, Australia). The Gentian CysC 
calibrator was standardised against the international standard 
ERM-DA471/IFCC. The range of the assay is 0.34-7.95 mg/L. The 
intra- and inter-assay precision for samples with concentrations in 
this range is <10% (Beckman), and this was confirmed under our ex-
perimental conditions (our coefficient of variation was 7%).
Serum and plasma creatinine concentrations were measured 
using a kinetic modification of the Jaffe procedure on the Beckman 
DXCi biochemistry analyser (Beckman Coulter, Australia) using a 
commercial calibrator which is traceable to an isotope dilution mass 
spectrometry (IDMS) reference method using the National Institutes 
of Standards and Technology (NIST) Standard Reference Material 
967. (Beckman Coulter DxCi Creatinine Package Insert).
2.1 | Recruitment and statistical analysis
Convenience sampling method was used to recruit patients. All eligi-
ble neonates with parental consent were recruited. The normality of 
the variables was determined by the D'Agostino-Pearson test.11 The 
results are expressed as the means and (standard deviation [SD]) for 
continuous normally distributed data and as median (interquartile 
range [IQR]) for continuous non-normally distributed data. One-way 
analysis of variance (ANOVA) will be used to test the difference be-
tween the means of several subgroups of a variable. Pearson's cor-
relation coefficient (r) will be used to measure of the strength of the 
association between the two variables. Comparisons of means of 
normally distributed data were made using t tests, and P value < .05 
was considered statistically significant. Statistical analyses were 
performed using MedCalc for Windows, version 16.4.3 (MedCalc 
Software).
Key Notes
• Serum Cystatin C level is independent of body weight 
and not influenced by postnatal age nor by gender.
• There is a gradual decline in Cystatin C level from the 
corrected term period until the age of two when it 
plateaus.
• Cystatin C has the potential to become the primary bio-
marker to assess renal function in neonates
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3  | RESULTS
A total of 131 premature neonates <28 weeks gestation were admit-
ted to the neonatal unit. We recruited 58 neonates with gestation 
<28 weeks, and there were nine deaths. Data from 45 patients were 
available at 28 weeks corrected for analysis, with none being diag-
nosed as having Acute kidney injury. The mean gestation was 26.2 
(1.5) weeks, and the mean birth weight was 917(140) g. One-way 
analysis of variance (ANOVA) did not show any significant difference 
in CysC level between 28, 32 and 37 weeks of age (P = .09) although 
a significance increases body weight (P < .001) (Figure 1). We also 
recruited 29 term neonates (gestation > 37 weeks), and there was 
no significant difference in CysC level between preterm infants (at 
37 PMA) and term infants (1.61(0.3) vs. 1.62(0.27) mg/L; P = .84), 
respectively. There was significant correlation between body weight 
and Scr level in premature neonates from 28 to 37 weeks (r = −.61, 
P < .001).
The mean CysC level was higher in the neonatal period and had 
plateaued by 24 months (Figure 2). There was no correlation be-
tween body weight and CysC levels at the respective age groups, as 
shown in Table 1. There was no difference between male and female 
neonates. Serum creatinine levels were 48.6(18.2), 21.2(6.2) and 
16.2(6.3) umol/L at 28, 32 and 37 weeks, respectively.
4  | DISCUSSION
Our data show that CysC levels remain constant between 28 and 
37 weeks of gestation. Subsequently, there is a decline in the CysC 
level in the first two years of life. There was no difference in CysC 
levels between preterm (at 37 weeks PMA) and term neonates. CysC 
was also independent of body weight. We believe these proper-
ties as well as the fact that it is freely filtered at the glomerulus and 
does not undergo tubular reabsorption make CysC a more reliable 
biomarker of glomerular filtration rate than SCr.6 We propose that 
clinicians should routinely use CysC to determine glomerular filtra-
tion rate in infants. CysC can be used to calculate estimated GFR 
(eGFR).12
Nakashima et al published a longitudinal study which involved 
261 preterm infants, which were divided into three groups based on 
the gestational age (27-30 weeks, 31-33 weeks and 34-36 weeks) 
and followed these infants up for the first year of their lives.13 Serum 
CysC levels were measured at 6-30 days, 3-5 months, 7-9 months 
and 12-14 months after birth. The investigators reported that there 
was no difference in the CysC level between the three groups, and 
CysC level decreased in the first year of life, similar to our results. In 
another study, Bardallo et al investigated a cohort of 109 preterm 
neonates.14 The infants were divided into three groups: Group A 
F I G U R E  1   Cystatin C levels (mg/L) at postnatal age of 28, 32 
and 37 wk
F I G U R E  2   Cystatin C levels (mg/L) in 
the first 2 y of life after discharge from 
the neonatal unit
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(24-27 weeks), Group B (28-33 weeks) and Group C (34-36 weeks). 
Blood samples were collected at birth, within 48-72 h and after 
7 days of life. Serum CysC decreased within 48-72 h of life, and after 
7 days in all three groups, and there was no difference in CysC level 
between the different gestational age groups, quite similar to our 
findings.
Cystatin C is measured using an immunoassay, either a tra-
ditional enzyme-linked immunoassay (ELIZA) or an automated 
method using enhanced particle detection with either turbidome-
try (PETIA), nephelometry (PENIA) or immunofluorescence. Some 
studies are suggesting that the particle-enhanced nephelometric 
assays (PENIA) are more accurate than the immunoturbidometric 
assays (PETIA).15 However, inter-assay variability has been re-
duced through a harmonisation project, and the introduction of 
an International Federation of Clinical Chemistry and Laboratory 
Medicine (IFCC recommended) calibrator (ERM- DA471/IFCC).15 
Serum Cystatin C is a better indicator of AKI than eCCl (estimated 
creatinine clearance) within the first 24 hours.15 There a few hur-
dles that prevent CysC from being used more readily by clinicians. 
CysC is not readily available for clinicians, unlike SCr measure-
ments and the costs are higher. Recently, point care of testing for 
CysC (Eurolyser Diagnostica GmbH, Salzburg, Austria) has become 
available, which makes it more likely that clinicians will use this 
test of renal function.
The main limitation of this study is its relatively small sample size. 
Approximately 50% of the neonates that fulfilled the recruitment 
criteria were recruited. A significant proportion of the neonates ad-
mitted to the unit for regional area, and these neonates are often 
transferred back to their regional hospital for ongoing management 
once they are slightly more mature. Some parents were unable to 
commit to two years follow-up due to various reasons, hence the 
attrition seen in the follow-up cohort. We were unable to determine 
whether growth restricted and large for gestational age neonates 
have a different CysC level. We were also unable to provide both 
SCr measurements for the whole cohort as after discharge from the 
neonatal unit, we opted for a less invasive blood collection method 
for older infant, using finger prick. This is to reduce discomfort the 
older child. However, limitations of this approach included the lim-
ited amount of specimen collected each time, sufficient for CysC 
measurement only and the higher chance of haemolysis with this 
technique due to squeezing, and that would interfere with the Jaffe 
method used for SCr measurements.
5  | CONCLUSION
Our study shows that serum CysC levels are independent of body 
weight and postnatal age and gender. There is a gradual decline in 
CysC levels from those measured at corrected term age period on-
wards until the age of two. CysC has features that make it a more 
reliable biomarker for the clinician.
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